Genovis completes a strategic investment in SEQURNA, a developer of next-generation RNase inhibitors
This strategic investment unlocks new product offerings for Genovis to both existing and new customers and further paves the way for the expansion into new application areas. Genovis will utilize its distribution network to market and sell SEQURNA’s RNase inhibitors alongside its own catalogue of innovative tools for the biopharmaceutical and research industries.Following the investment, Genovis will own 25 percent of SEQURNA. As part of the transaction, the parties have agreed to a call option with an end date on 30 June 2027, providing Genovis the right to acquire all shares of SEQURNA